These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 4917326)

  • 41. [Increase of fibrinolytic activity and reduction of platelet adhesiveness caused by prolonged treatment with ethyl-chloro-phenoxy-isobutyrate].
    Frandoli G; Gibelli A; Giarola P
    Clin Ter; 1966 Jul; 38(1):27-38. PubMed ID: 4230052
    [No Abstract]   [Full Text] [Related]  

  • 42. Mode of action of chlorophenoxyisobutyric acid on cholesterol metabolism in man.
    Horlick L; Kudchodkar BJ; Sodhi HS
    Circulation; 1971 Feb; 43(2):299-309. PubMed ID: 5540713
    [No Abstract]   [Full Text] [Related]  

  • 43. Rationale for use of lipid-lowering drugs.
    Dayton S
    Fed Proc; 1971; 30(3):849-56. PubMed ID: 5575297
    [No Abstract]   [Full Text] [Related]  

  • 44. [Inborn errors of lipid metabolism. Effect of clofibrate on the level of blood lipids of patients with familial hyperlipoproteinemia (type 2, 3 and 4)].
    Sobra J; Heyrovský A; Sulc M; Horáková D
    Cas Lek Cesk; 1969 Aug; 108(36):1065-9. PubMed ID: 5807234
    [No Abstract]   [Full Text] [Related]  

  • 45. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 46. [The therapeutic use of CPIB in pathological increase of the lipid constituents of the blood].
    Cloarec M; Cottet J; Etienne J; Loeper J
    Sem Ther; 1965 Nov; 41(9):499-500. PubMed ID: 5877602
    [No Abstract]   [Full Text] [Related]  

  • 47. Familial hypercholesterolaemic xanthomatosis and coronary heart disease in a ten-year-old girl.
    Miettinen M
    Ann Paediatr Fenn; 1967; 13(1):35-8. PubMed ID: 6079714
    [No Abstract]   [Full Text] [Related]  

  • 48. [Medical treatment of hyperlipemia. Indications and modern preparations].
    Frey H
    Tidsskr Nor Laegeforen; 1968 Jan; 88(2):6-8. PubMed ID: 5663311
    [No Abstract]   [Full Text] [Related]  

  • 49. Dietary fat restrictions and atromid therapy in patients with type II familial hyperlipoproteinemia.
    Sanbar SS; Zweifler AJ; Conway J
    Mich Med; 1968 Nov; 67(21):1346-7. PubMed ID: 5699513
    [No Abstract]   [Full Text] [Related]  

  • 50. [Derivatives of para-chlorphenoxyisobutyric acid as hypocholesteremic agents].
    Klebanov BM
    Farmakol Toksikol; 1970; 33(3):324-7. PubMed ID: 5453029
    [No Abstract]   [Full Text] [Related]  

  • 51. A comparison of platelet stickiness tests during an atromid-S trial.
    O'Brien JR; Heywood JB
    Thromb Diath Haemorrh; 1966 Dec; 16(3):768-77. PubMed ID: 5996687
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clofibrate in the management of a case of lipoid dermato-arthritis: a clinical and metabolic study.
    Golding DN
    Ann Rheum Dis; 1968 Sep; 27(5):475-6. PubMed ID: 5677165
    [No Abstract]   [Full Text] [Related]  

  • 54. Hyperlipoproteinemias in the prematurely aged. Theories of pathogenesis, diagnosis, classification, and treatment.
    Herrmann GR
    Geriatrics; 1970 Apr; 25(4):103-14. PubMed ID: 5443794
    [No Abstract]   [Full Text] [Related]  

  • 55. Hyperlipaemia in experimental nephrosis and its control by chlorophenoxyisobutyrate and betabenzalbutyrate.
    Edwards KD; Paoletti R
    Med J Aust; 1970 Mar; 1(10):474-7. PubMed ID: 5440989
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of chlorophenoxy-isobutyric ester on platelet adhesiveness and aggregation in the patients with arteriosclerosis and diabetes mellitus].
    Yasunaga K
    Naika Hokan; 1969 Oct; 16(10):393-403. PubMed ID: 5391800
    [No Abstract]   [Full Text] [Related]  

  • 57. [Abnormal lipid metabolism and coronary insufficiency].
    Murakami M; Sekimoto H; Tanaka I; Seo M; Takegoshi T
    Saishin Igaku; 1970 Jan; 25(1):101-9. PubMed ID: 5450347
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of hyperlipidemias with para-chlorphenoxyisobutyric acid (Regardin)].
    Bruns W; Jung HD
    Dtsch Gesundheitsw; 1971 Feb; 26(8):359-61. PubMed ID: 5576676
    [No Abstract]   [Full Text] [Related]  

  • 59. [Changes of the coefficient of peripheral utilization of glucose after venous administration, in hypercholesteremic subjects, after treatment with an antidyslipidemic agent].
    Pasini P
    G Gerontol; 1969 Aug; 17(8):808-16. PubMed ID: 5371744
    [No Abstract]   [Full Text] [Related]  

  • 60. [Clinical and biological trials of C.P.I.B.-aluminium].
    Jouve A; Avril P; Mary Y; Pierron J; Pons JC
    Mars Med; 1970; 107(8):575-88. PubMed ID: 5450599
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.